Neximmune announces presentations at the society for immunotherapy of cancer's 38th annual meeting

Gaithersburg, md., oct. 19, 2023 (globe newswire) -- neximmune, inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming society for immunotherapy of cancer (sitc) 38th annual meeting in san diego, ca , being held november 1-5, 2023.
NEXI Ratings Summary
NEXI Quant Ranking